MedTrace Logo

Using End-Tidal CO₂ to Help Diagnose and Monitor Pulmonary Embolism

NCT07241130 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 120

Last updated 2025-12-22

No results posted yet for this study

Summary

Pulmonary embolism (PE) can reduce blood flow in the lungs and impair gas exchange, leading to lower end-tidal carbon dioxide (EtCO₂) levels. This prospective observational study aims to evaluate whether EtCO₂ can help identify high-risk and intermediate-high-risk patients and monitor early treatment response, especially during thrombolytic therapy. A total of 120 participants were included: high-risk PE, intermediate-high-risk PE patients who received thrombolysis, intermediate-high-risk PE patients treated only with anticoagulation, and healthy controls.

The study measured EtCO₂ along with oxygen saturation, heart rate, respiratory rate, perfusion index, and radiological obstruction scores. By comparing these parameters at diagnosis and during the first 24 hours, the study seeks to determine whether EtCO₂ can serve as a simple, noninvasive marker of disease severity and early hemodynamic improvement in patients with acute PE.

Conditions

  • Pulmonary Embolism Acute

Interventions

OTHER

thrombolytic therapy

Participants received standard clinical management according to current pulmonary embolism guidelines. No intervention was assigned by the investigators.

Sponsors & Collaborators

  • Ataturk University

    lead OTHER

Eligibility

Min Age
18 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-02-01
Primary Completion
2025-07-30
Completion
2025-07-30

Countries

  • Turkey (Türkiye)

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07241130 on ClinicalTrials.gov